

FORESIGHT

Health~Holland programma

Liesbeth de Vries, Guus van Dongen, John Haanen, Peter de With:
program leaders

Elena Merlo: Innovation Center UMCG

Informatie sessie 1 July 2026

Agenda

- FORESIGHT: vision and objectives
- FORESIGHT Health~Holland programma: procedure, criteria

FORESIGHT webpage: <https://umcgresearch.org/w/foresight-ppp-program>

Background FORESIGHT Center

- FORESIGHT combines complementary infrastructure and expertise in clinical care, research, imaging techniques, biomedical engineering, drug development, and data processing. The aim of this ongoing collaboration is to use molecular imaging to advance drug development and personalized drug treatment for patients with **cancer** and **autoimmune, cardiovascular, and neurodegenerative diseases**.
- Many (inter)national companies and institutions have expressed a need for the FORESIGHT model. That is why we want to realize an optimally functioning FORESIGHT Service and Innovation Center. The Center provides infrastructure for innovative drug trials with molecular imaging, innovation, education, and support for regulatory issues.


FORESIGHT Program: aim and budget

- The aim of the FORESIGHT-PPS program, financially supported by Health~Holland, is to carry out, within the Center, projects in **drug development or choice with molecular imaging** in these four disease areas, using one or more of the modules: tracer production, imaging, and data analysis/AI, to demonstrate added value of the FORESIGHT proposition.
- The FORESIGHT PPP program grant enables the creation of these showcases with (inter)national partners and strong participation from Dutch SMEs/start-ups.
- Awarded 9M€, 3M€ every year from Health~Holland for 2025-2027.

The investments in the FORESIGHT program result in 6 main outputs:

1. Technical design and innovation in the field of tracer development, molecular imaging, and data analysis/AI.
2. Optimal harmonization of procedures used.
3. Demonstrate added value, impact, and increased success rate of drug development and better drug choices for the individual patient through the use of molecular imaging.
4. Better accessibility to molecular imaging, especially for Dutch pharma and SMEs/start-ups.
5. Acceleration in setting up and expanding the Center's propositions.
6. Better (inter)national visibility of the Center.

FORESIGHT governance



Procedure project grants

- The FORESIGHT program lasts 8 years, from 1 January 2025 to 31 December 2032
- Project duration max 4 years
- Application options in 2025, 2026, 2027 -> pre-proposal is required!
- All templates available on the website, including: pre- and full application forms, budget form, commitment letters, and checklist
- Information procedures and criteria are shared via:
- Foresight page <https://umcgresearch.org/w/foresight-ppp-program>
 - Health~Holland website
 - Online Information sessions
 - Slides of the information sessions
 - Direct FORESIGHT email: foresight@umcg.nl

The scoring template contains all questions to assess whether TKI-LSH eligibility requirements, including financial requirements, are met.

- A link with a member of the core module or disease area teams, and at least a private and a public partner
- Carried out within the center
- Contribution to FORESIGHT objectives and appropriate output. Most project proposals have a technology readiness level ≥ 4 : Development phase (TRL 4, 5, and 6), Demonstration phase (TRL 7 & 8)
- Innovative public-private R&D development project in drug development with molecular imaging in one of the 4 disease areas, using one or more modules
- Duration preferably 3 to a maximum of 4 years
- Dissemination to the scientific community and the wider public
- Social impact
- Economic impact
- Good quality, partly in view of the feasibility and mitigation plan
- Collaboration with companies in the Netherlands, SMEs, and public partners, such as healthcare providers, patients, & insurers.
- Maximum scale ~€1,500,000, of which €750,000 is a subsidy, 50% contribution by public-private parties, of which a minimum of 10% is a cash contribution for large companies
- Subsidy for SMEs

Content criteria at portfolio level

- The goal is a **balanced project portfolio** contributing to the overarching goals of the FORESIGHT Center.
- Yearly the composition and total project size relate to the realized and expected output and impact is analyzed.
- Aim: **diversity in partners**, including academic institutions, healthcare institutions, SMEs, large (inter)national industries, and public organizations such as patient organizations, that contribute both in cash and in-kind.
- **Private parties**, especially Dutch SMEs/start-ups, are crucial for flexibility and innovation. In addition to financial contributions from large companies, their active involvement in development and commercial roll-out is essential. This will enable international companies to connect more strongly with the Netherlands and increase export opportunities.
- The participation of public end-users in project consortia increases the likelihood of successful implementation of innovations in practice.

So far

2 completed rounds for 2025 & 1 pre-proposal round for 2026

- **1st round 2025**

- 6 preapplications, of which 2 full proposals have been awarded
- [SILENCE - imaging to optimise antibody-based therapies](#)
- [IMPACT HF - Imaging the Cardiac Diet: How Failing Hearts Burn Fuel](#)
- **2nd round 2025**
 - 9 preapplications, of which 3 full proposals were selected (documents in finalization)
- **1st round 2026**
 - 5 preapplications selected for full submission (1 October)

Funding conditions

- All consortium partners must make an in-kind contribution.
- A partner that receives a PPP subsidy cannot contribute cash to the project.
- Dutch SME that requests subsidy should demonstrate to be financially sound.
- The budgeted, subsidised costs directly relate to the R&D activities and do not include non-eligible costs.
- Average project side $\leq$ €1,500,000, of which €750,000 PPP subsidy, 50% contribution by parties involved.
- For large companies, a minimal 10% cash contribution to the total budget is requested, plus an in-kind contribution.

Table 1.A: Funding by type of research at partner level

Max % PPP subsidy based on eligible costs partner	Fundamental and industrial research	Experimental development
Research organization	70%	60%
Dutch SME	60%	40%
Large enterprises, non-Dutch SME, Dutch and non-Dutch other parties	0%	0%

The percentages listed in Table 1.A are percentages taken over the total costs of the organization in question.

Table 1.B: Minimal contributions at project level

Minimal contribution based on total project cost	Fundamental and industrial research	Experimental development
Research organization(s)	min. 10%	min. 10%
For-profit and not-for-profit enterprise(s)	min. 15%	min. 30%

The percentages listed in Table 1.B are percentages taken over total project costs.

Given financial conditions presented, project budgets can not be finalized without additional negotiations among project partners. Please consult a TTO/ Business developer for negotiations with commercial partners, when necessary.

Common questions received

Can the project include fundamental research?	Only in a limited amount. The vast majority of the activities and costs should be in industrial / experimental research
Can foreign companies join?	Yes, both SMEs or large industries, however they are not eligible for funding.
Can an organization contribute in cash to the project?	Yes, however that organization is not eligible for funding.
Can the project involve implementation activities?	Yes, but only up to TRL 7, higher than that is not eligible for funding.
Can the project include a clinical trial?	Yes, but only phase 1 and phase 2a.
Can the project be a sponsored study?	No, the project should be an effective collaboration following the Health~Holland rules for join efforts, join risks and join contribution.
Can a new partner be added after pre-proposal is selected?	No, as this will be major change and would need a new evaluation
Can the budget change after the pre- proposal is selected?	Preferably not. Prompt notification, only minor change (5-10%), within the budget criteria if subsidy is available

Direct email contact: foresight@umcg.nl

- Patent applications and maintenance (costs for patents purchased on arm's length terms from or licensed by external sources are eligible)
- Audit
- Bench fee (note: material costs are eligible)
- Domestic travel
- Support staff, not directly related to the substantive R&D activities, such as: project controller, business developer, administrative assistant
- Developing a business case
- Costs related to implementation of developed innovation (preparation of MDR technical documentation and risk assessments are not allowed!)
 - Activities R&D related or that will contribute to improving design, or collecting critical technical considerations for concept development and industrial design, that feed back to the R&D cycle are allowed (e.g., testing safety, usability, mechanics)
 - Creating a clinical roadmap is allowed but should be well substantiated. Not allowed are medical device consulting on Regulatory & Quality, Clinical risks (phase 3 and beyond), supply chain, and market assessments)
- Conducting a Health Technology Assessment (HTA)
- Overhead
- Non-scientific dissemination, information material, and marketing material. But scientific dissemination, including attending a scientific conference or publishing a scientific article, is eligible
- Project management activities that are not directly related to the substantive R&D work, including escalation of issues to the Steering Committee, development of a risk management framework, preparation of reports to fulfill grant reporting obligations, and administrative and financial accountability. But project management tasks directly related to substantive R&D activities (e.g., discussions with employees, analysis of technical risks, preparation of substantive reports, and preparation of specifications) are eligible

Application process call Autumn 2026

Phase	Timelines of 2026	Description
Information sharing	Open, anytime	Website https://umcgresearch.org/w/foresight-ppp-program Contact foresight@umcg.nl
Pre-application phase	01/07-01/11/2026	Submission of pre-application form and preliminary budget; Status of project discussions with the company Templates provided on Foresight website
<i>Outcome</i> <i>Selection pre-proposals</i>	By 1 December 2026	Pre-proposal are evaluated, a selection is made
Full application phase	01/12 – 28/02/2026	Submission of full application form and definitive budget; Advanced draft collaboration agreement
<i>Final Decision</i> <i>Awarded proposals</i>	By 1 April 2026	Decision is communicated to the applicant on a timely manner. Request to complete all documentation (including agreement, data management plan, project profile, etc)
Finalization documents awarded proposals	By 1 May 2026	Registration in RVO database : Final application, budget, RVO form, Project profile are submitted to Health Holland for final check and registration RVO database. Draft agreement in place
	By 1 July 2026	All documentation is ready Contract agreement is signed Award letter shared

Next rounds

- €3 MLN PPP subsidy is available in 2026
 - 5 pre-proposals were selected in the First Call of 2026
 - The second funding call for 2026 is open until 1 November
- Depending on the status of applications, applicants may be advised to resubmit
- Upon confirmation, the €3 MLN PPP subsidy is also expected in 2027
 - Definitive allocation will be confirmed by Health Holland in January 2027
 - It is expected that 1-2 calls will also be open in 2027

Contact

- Website for general information, templates, slides, contact info
<https://umcgresearch.org/w/foresight-ppp-program>
- Direct email contact: foresight@umcg.nl

Program coordinators: Liesbeth de Vries (UMCG), Guus van Dongen (AUMC), John Haanen (NKI), Peter de With (TU/e)

Please consult TTO offices at partner institution for support in preparing applications